How to Get Leqvio (Inclisiran) in Minnesota

What Is Leqvio and Why Minnesota Patients Are Asking About It

Leqvio is the first small interfering RNA (siRNA) therapy approved by the FDA for lowering LDL cholesterol, targeting PCSK9 synthesis directly in hepatocytes. It is indicated for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C reduction on top of maximally tolerated statin therapy. 1

Two phase 3 trials published in the New England Journal of Medicine in 2020 confirmed its efficacy. ORION-10 (N=1,561, United States population) showed a time-averaged, placebo-adjusted LDL-C reduction of 52.3% at day 510 (P<0.001). 2 ORION-11 (N=1,617, European and South African population) showed a 49.9% time-averaged reduction over the same period (P<0.001). 2 Both trials reported a side-effect profile comparable to placebo, with injection-site reactions occurring in about 2.6% of inclisiran recipients.

Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab (Repatha) or alirocumab (Praluent), which require injections every two to four weeks, inclisiran is dosed twice yearly after two loading injections. 3 That schedule makes adherence substantially easier for most working adults. Minnesota-specific interest in the drug has grown since Novartis launched an expanded specialty pharmacy network in 2023.

The American College of Cardiology and American Heart Association 2022 cholesterol guideline update identifies PCSK9 inhibition as a class I recommendation for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy. 4

Who Qualifies for Leqvio in Minnesota

The FDA label limits inclisiran to two populations: adults with HeFH and adults with ASCVD. 1 Qualification depends on documented diagnosis and a therapeutic gap despite existing lipid-lowering therapy.

Heterozygous familial hypercholesterolemia requires either genetic confirmation or a clinical diagnosis using Dutch Lipid Clinic Network (DLCN) criteria scoring at or above 6, or the Simon Broome criteria. 5 A DLCN score of 6 to 8 is classified as probable HeFH; a score above 8 is definite. Minnesota clinicians may use either set of criteria, and Minnesota Medicaid accepts both for prior authorization purposes.

Established ASCVD encompasses prior myocardial infarction, ischemic stroke, peripheral arterial disease, or coronary revascularization. Documentation must come from medical records, operative notes, or imaging reports. An echocardiogram alone does not satisfy the ASCVD criterion without concurrent coronary artery disease findings.

LDL-C threshold requirements vary by payer. Most commercial plans in Minnesota require LDL-C at or above 70 mg/dL for ASCVD patients and at or above 100 mg/dL for HeFH patients, measured while the patient is on a stable statin dose for at least 4 weeks. 6 Some plans specifically require a 4-week trial of rosuvastatin 40 mg or atorvastatin 80 mg before approving inclisiran.

The HealthRX clinical team uses a three-gate qualification screen for inclisiran candidates:

1. Confirmed HeFH by genetic test or DLCN score, OR documented ASCVD event
2. LDL-C at or above the payer threshold on maximally tolerated statin, with or without ezetimibe 10 mg
3. No active liver disease (ALT or AST above 3 times the upper limit of normal contraindicates use per the FDA label)

Patients who pass all three gates move directly to prior authorization preparation.

Labs Required Before Starting Leqvio in Minnesota

Most Minnesota prescribers and payers require a specific set of labs drawn within 90 days of the prior authorization submission. 7

The standard panel includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides). LDL-C must be calculated or directly measured while on a stable lipid-lowering regimen.
• Comprehensive metabolic panel (CMP) to assess hepatic function. The FDA label states inclisiran should not be initiated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases. 1
• eGFR or serum creatinine to document renal function. No dose adjustment is required for renal impairment, but baseline documentation is standard for specialty pharmacy approval. 8
• HbA1c if the patient has diabetes, as cardiometabolic context aids prior authorization narratives for some Minnesota commercial plans.

Genetic testing for LDLR, APOB, or PCSK9 mutations is not required by most payers for ASCVD patients but is strongly recommended for HeFH patients to satisfy DLCN genetic confirmation criteria and may reduce the likelihood of PA denial. 5 GeneDx and Invitae both ship collection kits to Minnesota home addresses with return prepaid; results typically arrive in 10 to 21 business days.

Repeat lipid panels are recommended at 90 days after the first injection, then every 6 months before each subsequent dose per Novartis prescribing information. 1

How to Get a Leqvio Prescription in Minnesota: Step by Step

Getting a Leqvio prescription in Minnesota requires five distinct steps, and understanding each one prevents weeks of unnecessary delay.

Step 1. Establish care with a licensed MN prescriber. Any licensed physician (MD or DO), nurse practitioner (APRN with prescriptive authority), or physician assistant (PA-C with supervising agreement) holding an active Minnesota prescriber registration may write an inclisiran prescription. 9 Cardiologists and lipidologists are the most common prescribers, but primary care physicians with a valid DEA registration and MN medical license may also prescribe. Telehealth consultations with a clinician licensed in Minnesota satisfy the state's prescribing requirements, provided the consultation meets Minnesota Statute 147.37 standards for establishing a valid patient-provider relationship.

Step 2. Order the required labs. Draw the fasting lipid panel, CMP, and any supporting documentation as listed in the previous section. Labs drawn within 90 days are accepted by most Minnesota commercial carriers including UCare, Blue Cross Blue Shield of Minnesota, Medica, and HealthPartners.

Step 3. Prepare and submit the prior authorization. PA submissions require: the ICD-10 diagnosis code (E78.01 for HeFH, or the appropriate ASCVD code such as I25.10 for coronary artery disease), current LDL-C with date drawn, a list of previously trialed statin doses and any documented intolerance, and the prescribing clinician's NPI. Minnesota Medicaid (Medical Assistance) covers inclisiran with PA for both HeFH and ASCVD indications. Processing typically takes 3 to 14 business days for commercial plans; Medicaid PA can extend to 21 days. 10

Step 4. Specialty pharmacy dispensing. Leqvio is distributed exclusively through Novartis's Specialty Linked Care network, which includes specialty pharmacies operating in Minnesota such as Accredo, Briova, and CVS Specialty. The pharmacy ships the drug directly to the administering clinic, not to the patient's home, because it must be given by a healthcare professional. Typical pharmacy processing and shipping time is 5 to 10 business days after PA approval.

Step 5. In-clinic administration. The injection is given subcutaneously in the abdomen, upper arm, or thigh by a licensed clinical professional. Day 1 and Day 90 injections constitute the loading phase; subsequent injections occur every 6 months. The drug should not be self-administered. 1

Telehealth Providers Prescribing Leqvio in Minnesota

Telehealth prescribing of inclisiran is permitted in Minnesota for providers holding a valid MN prescriptive authority credential. 9 The Minnesota Board of Medical Practice does not require an in-person physical examination before a prescriber writes a specialty lipid-lowering agent, provided the telehealth encounter satisfies the standard of care for history-taking, review of labs, and documentation.

Several national telehealth platforms have added inclisiran to their specialty cardiology offerings for Minnesota patients, including services associated with academic medical systems and direct-to-patient telehealth companies. A cardiologist or lipidologist conducting a synchronous video visit can review lab results, confirm diagnosis, and submit a PA on the same day as the consultation.

The American Telemedicine Association notes that synchronous audio-video encounters satisfy most payer requirements for specialist consultations when no physical examination finding is required for the prescribing decision. 11 For inclisiran, the prescribing decision rests on lab values and documented diagnosis rather than physical exam findings, making telehealth a practical pathway.

Patients in rural Minnesota counties, including those served by critical access hospitals, should verify that their telehealth provider's NPI is enrolled in Minnesota Medical Assistance if they intend to use Medicaid coverage, because provider enrollment is required for Medicaid reimbursement regardless of telehealth modality. 10

After the telehealth consultation and PA approval, the drug still ships to a clinical site for administration. Patients should plan for at least one in-person visit every 6 months. Some Minnesota federally qualified health centers (FQHCs) and large cardiology practices offer injection appointments that do not require a separate full office visit, billed as drug administration codes (96372 or J3490 for unlisted injections, depending on plan contracts).

Prior Authorization Requirements in Minnesota: What Documentation You Need

Prior authorization is required by nearly every commercial and public payer in Minnesota for inclisiran. Preparing complete documentation at the first submission reduces denial rates and avoids the 30 to 45 days often lost during appeal cycles.

A complete PA packet for Minnesota plans should include:

1. Diagnosis documentation. ICD-10 code plus supporting evidence (genetic test report for HeFH, or procedure/hospitalization records for ASCVD events). 5
2. Current LDL-C value with the lab date and the concurrent statin regimen documented in the chart note.
3. Step therapy documentation. Evidence of a trial at maximally tolerated statin dose, typically rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg, for a minimum of 8 weeks. 4 If statin intolerant, a note documenting myopathy, elevated CK, or physician-confirmed intolerance with at least two statin trials is required by most MN commercial plans.
4. Ezetimibe trial. Several Minnesota payers, including BCBS MN and HealthPartners, require a 90-day trial of ezetimibe 10 mg before approving PCSK9-targeting agents for ASCVD patients not meeting a very high-risk threshold.
5. Prescriber attestation confirming the patient has an established clinical relationship and the diagnosis is consistent with FDA-approved indications.

The ACC/AHA 2022 guideline states: "For very high-risk patients with ASCVD and LDL-C 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)." 4 Quoting this specific language in the PA narrative, with the guideline citation, materially strengthens approval probability.

Minnesota Medicaid (Medical Assistance) processes PA requests through the DHS Pharmacy Prior Authorization unit. Clinicians may submit electronically through MN-ITS or by fax. Approval decisions for non-urgent PA requests arrive within 14 calendar days; urgent requests are processed within 72 hours. 10

For denied PAs, Minnesota law requires an internal appeal decision within 30 days of the appeal request. If the internal appeal fails, patients may request an external independent review through the Minnesota Department of Commerce. 12

Cost and Copay Assistance for Leqvio in Minnesota

Leqvio carries a list price above $3,000 per dose, making out-of-pocket cost a real access barrier for uninsured and underinsured Minnesota patients. 1

Novartis operates the Leqvio Complete Support program, which includes a copay card for commercially insured patients that may reduce cost to $0 per dose for eligible individuals. Eligibility excludes patients covered by federal programs (Medicare Part D, Medicaid, TRICARE). Minnesota patients can enroll at the time of PA approval through the specialty pharmacy or directly through Novartis.

For patients with Medicare Part D coverage, the Novartis Patient Assistance Foundation offers income-based free drug programs. Eligibility is generally set at household income at or below 400% of the federal poverty level. Minnesota residents who are Medicare beneficiaries and meet income criteria may receive inclisiran at no cost through this program; applications require a completed form from the prescribing provider, a copy of Part D coverage documentation, and proof of income.

The ACC notes that the net cost of inclisiran to health systems may be offset by cardiovascular event reduction. A cost-effectiveness analysis published in JACC in 2022 estimated an incremental cost-effectiveness ratio (ICER) of approximately $450,000 per quality-adjusted life year (QALY) at list price, falling to approximately $20,000 per QALY when accounting for rebates and cardiovascular event costs avoided in very high-risk patients. 13 These economics directly influence formulary placement decisions by Minnesota managed care organizations.

503A Compounding Pharmacies and Inclisiran in Minnesota

Some patients ask whether a 503A compounding pharmacy in Minnesota can prepare inclisiran at lower cost. The answer requires precision. 14

503A pharmacies are licensed state-regulated pharmacies that compound drugs based on individual patient prescriptions. In Minnesota, 503A pharmacies are regulated by the Minnesota Board of Pharmacy and may compound certain drugs for individual patients. 15

Inclisiran is an FDA-approved drug. The FDA's compounding policy generally prohibits 503A pharmacies from compounding copies of commercially available FDA-approved drugs unless the drug is on the FDA's drug shortage list, which inclisiran currently is not. 14 Compounded inclisiran would not carry the same pharmacokinetic profile as the Novartis formulation validated in ORION-10 and ORION-11. Patients should be advised that only FDA-approved Leqvio (inclisiran sodium) 284 mg/1.5 mL solution has clinical trial evidence supporting its LDL-C reduction and safety profile. 2

Prescribers and patients in Minnesota considering a compounded alternative should be aware that payers will not cover compounded inclisiran, and the clinical risk-benefit profile of a compounded version is entirely undocumented.

How Long Until the First Dose in Minnesota: A Realistic Timeline

Patients frequently ask how long the process takes. A realistic end-to-end estimate for Minnesota patients follows, assuming no PA denial or appeal:

• Day 0: Telehealth or in-person consultation; labs ordered if not already available.
• Days 1 to 7: Lab results returned (standard turnaround at most Minnesota labs is 1 to 3 business days for a fasting lipid panel and CMP).
• Days 7 to 10: Prescriber reviews results, confirms qualification, submits PA with complete documentation.
• Days 10 to 24: PA decision received (3 to 14 business days for commercial plans; up to 21 days for MN Medicaid).
• Days 24 to 34: Specialty pharmacy processes the prescription and ships to the administering clinic (5 to 10 business days after PA approval).
• Days 34 to 42: Patient scheduled for in-clinic injection.

Total elapsed time from first contact to first injection: 5 to 6 weeks under favorable conditions. A PA denial requiring appeal extends this to 10 to 12 weeks. Patients with prior lipid labs on file and an established prescriber relationship may compress this to 3 weeks. 6

Transferring an Existing Leqvio Prescription to Minnesota

Patients relocating to Minnesota who already receive inclisiran may transfer their prescription within the Novartis Specialty Linked Care pharmacy network by notifying their specialty pharmacy of a new administering clinic in Minnesota. No new PA is required in most cases if the original approval remains active and the patient has not changed insurance.

If the patient's insurance plan changes upon relocation, a new PA is required under the new plan's criteria. The new Minnesota prescriber needs to verify the patient's diagnosis documentation is current and that the patient's LDL-C response to inclisiran has been monitored. Bring records showing the Day 1 and Day 90 injection dates, the most recent LDL-C result, and the original PA approval letter. Minnesota cardiologists and lipidologists at systems such as Mayo Clinic, M Health Fairview, Allina Health, and Park Nicollet regularly accept transferred specialty drug patients with adequate documentation.

Patients transferring from a Veterans Affairs facility to civilian care in Minnesota should note that the VA formulary covers inclisiran separately and that civilian specialty pharmacy logistics differ from VA mail-order distribution. The treating VA provider should supply a VA Transition of Care letter specifying the inclisiran dose schedule and most recent injection date.

Monitoring After Starting Leqvio in Minnesota

Ongoing monitoring is straightforward. A fasting lipid panel at 90 days after the first injection allows the prescriber to assess LDL-C response before the Day 90 loading injection. Subsequent lipid panels every 6 months, timed to each maintenance injection appointment, constitute the standard monitoring schedule. 1

The ORION-10 trial showed that LDL-C reductions are sustained over 18 months with twice-yearly dosing, with time-averaged reductions of 52.3% (P<0.001) compared to placebo. 2 Patients who do not achieve at least a 30% LDL-C reduction by the 90-day check should prompt a review of medication adherence, potential drug interactions, and whether concurrent statin therapy has been modified.

Liver function monitoring is not required on a routine schedule by the FDA label unless the patient has pre-existing hepatic disease, but many Minnesota clinicians include a CMP with each 6-month visit given payer documentation requirements and clinical prudence. 1

Cardiovascular outcomes data from the ORION-4 trial, expected in 2025, will provide definitive guidance on whether the LDL-C reductions observed with inclisiran translate to reduced MACE rates in a large outcomes trial. 16